Spravato is now the first-ever standalone therapy for treatment-resistant depression, and is on its way to becoming a blockbuster product.
The U.S. Food and Drug Administration approved Johnson & Johnson's ketamine-based nasal spray Spravato to treat adults with ...
The U.S. Food and Drug Administration has expanded the approval for Johnson & Johnson's nasal spray Spravato to allow its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback